Primary Aldosteronism: Are We Missing the Wood for the Trees?

Abstract

The prevalence of primary aldosteronism (PA) is around 10% of hypertensives, with markedly increased risk of cardiovascular damage compared with age-, sex- and BP-matched essential hypertension (EH). Currently, if hypertension is present in 20% of the population, PA will account for 2%; of these PA patients only 1% are ever screened, let alone diagnosed and treated, and the remaining 99% suboptimally treated, if at all. Mineralocorticoid receptor (MR) antagonists are effective in lowering BP, uniquely vasoprotective and safe when titrated to effect in EH. In resistant hypertension (BP elevated despite 3 or more conventional agents, including a diuretic), which constitutes 20–30% of EH, addition of a low dose MR antagonist reproducibly produces BP lowering of 20–30 mm Hg. Two thirds of PA is unilateral, and normally treated by MR antagonists; in unilateral PA surgery is recommended, but there are also studies reporting MR antagonist therapy to be noninferior over the longer term. There thus seems to be a very strong case for including a low dose MR antagonist in first-line therapy for new hypertension, given its utility and safety across EH, its particular efficacy in resistant hypertension, and its specific benefits for the 99% of subjects with occult PA. We do not have the resources to diagnose PA, but we do have the wherewithal to treat it.

Key words

guidelines - first-line therapy - public policy

• References

• 1 Auchus RJ. Primary aldosteronism and a Texas two-step. Rev Endocr Metab Disord 2001; 12: 37-42
• 2 Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90: 5070-5076
• 3 Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
• 4 Takeda Y, Karashima S, Yoneda T. Primary aldosteronism, diagnosis and treatment in Japan. Rev Endoc Metab Disord 2011; 12: 21-25
• 5 Oliveri O, Ciacciarelli A, Signorelli D, Pizzozo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Biengio G. Aldosterone to renin ratio in a primary care setting: the Bussolengo Study. J Clin Endocrinol Metab 2004; 89: 4221-4226
• 6 Levy D, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736-2740
• 7 Williams GH, Weinburger M, Lewin B, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminulla in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951
• 8 Calhoun DA.. Low dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich) 2007; 9: 19-24
• 9 Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 2010; 12: 1253-1260